The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results on long-term survival.
Rudolf Arnold
Honoraria - Novartis
Michael Wittenberg
No relevant relationships to disclose
Anja Rinke
Consultant or Advisory Role - Ipsen; Novartis
Honoraria - Ipsen; Novartis; Pfizer
Carmen Schade-Brittinger
No relevant relationships to disclose
Behnaz Aminossadati
No relevant relationships to disclose
Erdmuthe Ronicke
No relevant relationships to disclose
Thomas Mathias Gress
Honoraria - Novartis
Research Funding - Novartis
Hans Helge Mueller
No relevant relationships to disclose